European drugmakers announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums
More Stories
The Fed’s rate cut should make it easier to get a job — eventually. Here are the industries that could ramp up hiring first.
Some sectors are more likely to pick up hiring as borrowing costs fall. Here’s what that could look like.
Investors cheer a soft landing scenario after Fed’s big rate cut. But they’re still keeping their guard up for a downturn.
The Federal Reserve finally gave stock-market investors what they wanted this week by cutting interest rates for the first time...
As third-quarter earnings approach, here are the stocks that analysts like — and dislike — the most
This summer, shares of Amazon.com Inc., Microsoft Corp. and Nvidia Corp. each took a hit after the technology giants reported...
CDs paying 5% are a dying breed. Here’s how to find high savings rates while you still can.
Many 5% CDs are going away in the weeks after the Fed’s first interest-rate cut. Some have already disappeared.
Stocks poised for first September gain in 5 years. Why more good times could lie ahead.
September has historically been the worst month for U.S. stocks — but not this year